

such as patentable material and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Experimental Therapeutics Program (NExT) SEP February 2010 Cycle 3.

Date: April 30, 2010.

Time: 8:30 a.m.–4:30 p.m.

Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio.

Place: Doubletree Hotel Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Dr. Barbara Mroczkowski, Executive Secretary, NCI Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20817, (301) 496-4291, mroczkowskib@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 26, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-7346 Filed 3-31-10; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Review of NIAAA Member Application.

Date: April 7, 2010.

Time: 2 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Mark P. Rubert, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD 20892, 301-435-1775, rubertm@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 26, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-7345 Filed 3-31-10; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Aging Special Emphasis Panel; Effect of Energy Flux on Risk Factors for Age-Related Chronic Diseases. I

Date: May 3, 2010.

Time: 11 a.m. to 2 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, (Telephone Conference Call)

Contact Person: Ramesh Vemuri, PhD, Chief, Scientific Review Branch, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Suite 2C-212, Bethesda, MD 20892, 301-402-7700, rv23r@nih.gov.

Name of Committee: National Institute on Aging Special Emphasis Panel; Health Care Spending.

Date: May 5, 2010.

Time: 1:30 p.m. to 5:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C218, Bethesda, MD 20892, (Telephone Conference Call)

Contact Person: Alfonso R. Latoni, PhD, Deputy Chief, Scientific Review Branch, National Institute on Aging, 7201 Wisconsin Avenue, Suite 2C218, Bethesda, MD 20892, 301-402-7702, Alfonso.Latoni@nih.gov.

Name of Committee: National Institute on Aging Special Emphasis Panel; Diet Restriction.

Date: May 6, 2010.

Time: 1 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, (Telephone Conference Call)

Contact Person: Alicja L. Markowska, PhD, DSC, Scientific Review Officer, Scientific Review Branch, National Institute on Aging, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301-496-9666, markowska@nia.nih.gov.

Name of Committee: National Institute on Aging Special Emphasis Panel; Amyloid Imaging In Aging and Dementia.

Date: May 17, 2010.

Time: 11 a.m. to 2 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, (Telephone Conference Call)

Contact Person: Alexander Parsadanian, PhD, Scientific Review Officer, National Institute on Aging, Gateway Building 2C/212, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301-496-9666, PARSADANIAN@NIA.NIH.GOV.

Name of Committee: National Institute on Aging Special Emphasis Panel; Basis of Myocardial Injury in the Elderly.

Date: May 27, 2010.

Time: 1 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, (Telephone Conference Call)

Contact Person: Elaine Lewis, PhD, Scientific Review Officer, Scientific Review Branch, National Institute on Aging, Gateway Building, Suite 2C212, MSC-9205, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301-402-7707, elainelewis@nia.nih.gov.

Name of Committee: National Institute on Aging Special Emphasis Panel; Nutrient Signaling II.

Date: June 14, 2010.

Time: 12 p.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue,

Suite 2C212, Bethesda, MD 20892,
(Telephone Conference Call)

Contact Person: Bitu Nakhai, PhD,
Scientific Review Officer, Scientific Review
Branch, National Institute on Aging, Gateway
Bldg., 2C212, 7201 Wisconsin Avenue,
Bethesda, MD 20814, 301-402-7701,
nakhaib@nia.nih.gov.

Name of Committee: National Institute on
Aging Special Emphasis Panel; Adiposity,
Aging, and Stem Cells.

Date: June 23, 2010.

Time: 1 p.m. to 5 p.m.

Agenda: To review and evaluate grant
applications.

Place: National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue,
Suite 2C212, Bethesda, MD 20892,
(Telephone Conference Call)

Contact Person: Rebecca J. Ferrell, PhD,
Scientific Review Officer, National Institute
on Aging, Gateway Building Rm. 2C212, 7201
Wisconsin Avenue, Bethesda, MD 20892,
301-402-7703, ferrellrj@mail.nih.gov.

(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)

Dated: March 29, 2010.

Jennifer Spaeth,

*Director, Office of Federal Advisory
Committee Policy.*

[FR Doc. 2010-7344 Filed 3-31-10; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Development of PANVAC and Tumor Associated Antigens as Cancer Vaccines

AGENCY: National Institutes of Health,
Public Health Service, HHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in the following U.S. Patents
and Patent Applications to Bavarian
Nordic Immunotherapeutics ("BNIT")
located in Mountain View, CA, USA.

Intellectual Property:

1. U.S. Patent No. 6,756,038 issued
June 29, 2004 as well as issued and
pending foreign counterparts [HHS Ref.
No. E-099-1996/0-US-07];

2. U.S. Patent Application No. 10/
725,373 (recently allowed) filed
December 3, 2003 as well as
continuation and divisional
applications, and issued and pending
foreign counterparts [HHS Ref. No. E-
099-1996/0-US-08];

3. U.S. Patent No. 6,001,349 issued 14
Dec. 1999 as well as issued and pending
foreign counterparts [HHS Ref. No. E-
200-1990/3-US-01];

4. U.S. Patent Application No. 10/
579,025 filed May 11, 2006 as well as
all continuation and divisional
applications, and issued and pending
foreign counterparts [E-087-2005/0-
US-03];

5. U.S. Patent Application No. 10/
579,007 filed May 11, 2006 as well as
all continuation and divisional
applications, and issued and pending
foreign counterparts [E-088-2005/0-
US-03];

6. U.S. Patent No. 7,118,738 issued
October 10, 2006 as well as all
continuations and divisional
applications, and issued and pending
foreign counterparts [HHS Ref. No. E-
154-1998/0-US-07];

7. U.S. Patent Application Nos. 08/
686,280 filed July 25, 1996 as well as all
issued and pending foreign counterparts
[HHS Ref. No. E-259-1994/3-US-01];

8. U.S. Patent No. 7,410,644 issued
August 12, 2008 as well as all
continuation and divisional
applications, and issued and pending
foreign counterparts [HHS Ref. No. E-
259-1994/3-US-08];

9. U.S. Patent Nos. 6,893,869,
6,548,068 and 6,045,802 issued May 17,
2005, April 15, 2003 and April 4, 2000
respectively, as well as issued and
pending foreign counterparts [HHS Ref.
Nos. E-260-1994/1-US-03, US-02, US-
01]; U.S. Patent No. 7,368,116 issued
May 6, 2008 and U.S. Patent
Application No. 12/112,819, as well as
all continuation and divisional
applications [HHS Ref. Nos. E-260-
1994/1-US-04 and US-05];

10. Europe Patent Application No.
00102998.2 filed October 2, 1995,
Europe Patent No. 0784483 issued
November 29, 2001, Europe Patent
Application No. 09013495.8 filed
October 26, 2009, as well as all
continuation, and divisional
applications [HHS Ref. Nos. E-260-
1994/2-EP-15, EP-16 and EP-27]; Japan
Patent Application No. 512100/96 filed
October 2, 1995; Japan Patent No.
4078319 issued February 8, 2008 [HHS
Ref. No. E-260-1994/2-JP-25]; and
Japan Patent No. 4160612 issued July
25, 2008, as well as all continuation and
divisional applications; [HHS Ref. No.
E-260-1994/2-JP-21, JP-25 and JP-26];
Australia Patent No. 688606 issued July
2, 1998 [E-260-1994/2-AU-11]; Canada
Patent No. 2201587 issued June 25, 2002
[E-260-1994/2-CA-12];

11. Canada Patent Application No.
2,412,050 filed June 15, 2001 [HHS Ref.
No. E-187-2000/0-CA-05]; Australia
Patent No. 2001268452 issued

November 30, 2006 [HHS Ref. No. E-
187-2000/0-AU-06]; Japan Patent
Application No. 2002-510097 filed June
15, 2001 [HHS Ref. No. E-187-2000/0-
JP-07]; Hong Kong Patent Application
No. 03105975.5 filed June 15, 2001
[HHS Ref. No. E-187-2000/0-HK-08];
as well as all continuation and
divisional applications;

12. U.S. Patent Application No. 12/
280,534 filed February 21, 2007, [HHS
Ref. No. E-104-2006/0-US-06];
Australia Patent Application No.
2007221255 filed February 21, 2007
[HHS Ref. No. E-104-2006/0-AU-03];
Europe Patent Application No.
07751371.1 filed February 21, 2007,
[HHS Ref. No. E-104-2006/0-US-06];
filed February 21, 2007, [HHS Ref. No.
E-104-2006/0-EP-05]; Canada Patent
Application No. 2642994 filed February
21, 2007 [HHS Ref. No. E-104-2006/0-
CA-04]; as well as all continuation and
divisional and applications;

13. U.S. Patent Application No. 12/
528,796 filed August 26, 2009 [HHS Ref.
No. E-074-2007/0-US-07]; Australia
Patent Application No. 2008221383
filed February 27, 2008 [HHS Ref. No.
E-074-2007/0-AU-03]; Europe Patent
Application No. 08743578.0 filed
February 27, 2008 [HHS Ref. No. E-074-
2007/0-EP-05]; Canada Patent
Application No. 2,678,404 filed
February 27, 2008 [HHS Ref. No. E-074-
2007/0-CA-04]; Japan Patent
Application No. not yet assigned filed
February 27, 2008 [HHS Ref. No. E-074-
2007/0-JP-06] as well as all
continuation, divisional and pending
foreign counterpart applications;

Group II—Nonexclusive Licensed Patent Rights:

1. U.S. Patent No. 6,969,609 issued
November 29, 2005; U.S. Patent No.
7,211,432 issued May 1, 2007; U.S.
Patent Application No. 11/723,666 filed
March 21, 2007; as well as all
continuation and divisional
applications, and issued and pending
foreign counterparts [HHS Ref. No. E-
256-1998/0, 1];

2. U.S. Patent Application Nos. 60/
448,591 and 10/543,944 filed February
20, 2003 and February 20, 2004
respectively, as well as all continuation
and divisional applications, and issued
and pending foreign counterparts [HHS
Ref. No. E-028-2007/0];

3. U.S. Patent No. 6,699,475 issued
March 2, 2004, as well as all
continuation and divisional
applications, and issued and pending
foreign counterparts [HHS Ref. No. E-
134-2007/0];

4. U.S. Patent No. 5,093,258 issued
March 3, 1992, as well as all
continuation and divisional
applications, and issued and pending